Bicara Therapeutics BCAX Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Bicara Therapeutics's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Bicara Therapeutics (BCAX) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $0 in Q1 2026.